Lv1
34 积分 2025-08-20 加入
Phase 3, multicenter, randomized, controlled open-label study: Efficacy and safety of M701 (EpCAM×CD3 bispecific antibody) intraperitoneal infusion in advanced epithelial solid tumor with malignant ascites vs paracentesis
2个月前
已完结
Development and clinical trial of M701, an Anti-EpCAM × Anti-CD3 bispecific antibody: a targeted intraperitoneal therapy for malignant ascites stemming from advanced solid tumors
2个月前
已完结
Mechanistic prediction of first-in-human dose for bispecific CD3/EpCAM T-cell engager antibody M701, using an integrated PK/PD modeling method
2个月前
已完结
Efficacy of Bispecific Antibody Targeting EpCAM and CD3 for Immunotherapy in Ovarian Cancer Ascites: An Experimental Study
2个月前
已完结
Efficacy of Bispecific Antibody Targeting EpCAM and CD3 for Immunotherapy in Ovarian Cancer Ascites: An Experimental Study
6个月前
已完结
IMT030122, A novel engineered EpCAM/CD3/4-1BB tri-specific antibody, enhances T-cell recruitment and demonstrates anti-tumor activity in mouse models of colorectal cancer
7个月前
已完结
Nanobody-based bispecific antibody engagers targeting CTLA-4 or PD-L1 for cancer immunotherapy
1年前
已完结
Nanobody-based bispecific antibody engagers targeting CTLA-4 or PD-L1 for cancer immunotherapy
1年前
已完结
An armed anti-immunoglobulin light chain nanobody protects mice against influenza A and B infections
1年前
已完结
Nanobody-based bispecific antibody engagers targeting CTLA-4 or PD-L1 for cancer immunotherapy
1年前
已完结